Thalidomide for patients with severe autoimmune disease or autoinflammatory disease
Not Applicable
- Conditions
- Severe autoimmune disease or autoinflammatory disease who was refractory against standard treatment
- Registration Number
- JPRN-UMIN000034534
- Lead Sponsor
- Department of Pediatrics, Yokohama City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pulmonary tuberculosis, active bacterial infection or deep mycotic infection 2. Infection of HIV, HCV or HBV 3. Administraion of live vaccine within 4 weeks 4. Pregnant subjects or subjects who do not agree with contraception during the study period 5. Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method inhibition of disease activity
- Secondary Outcome Measures
Name Time Method improvement of physician's VAS, patient's VAS, biomarkers of disease activity and dose of corticosteroids